Search the Israeli drug index

Antivirals, Protease Inhibitors. nirmatrelvir 150 mg, Ritonavir 100 mg.
20 X FC pink tabs contain.150 mg of nirmatrelvir.
10 XFC white to off white tabs contain.100 mg of ritonavir.
Recomm. dosage is 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) all taken together orally every 12 hours for 5 days. This drug should be admin. as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.
Tmt. of confirmed coronavirus dis. 2019 (COVID-19) in adults
who do not require suppl. oxygen and who are at incr. risk for progressing to sev. COVID-19
C/I:  Hypersens.
Medic. prod. listed below are a guide and not considered a comprehensive list of all possible medic. prod. that are contraind. with this drug.
Medic. prod. that are highly dependent on CYP3A for clearance and for which elevated plasma concentr. are associated with serious and/or life-threatening reactions.
 Alpha1-adrenoreceptor antagonist: alfuzosin
 Antianginal: ranolazine
 Antiarrhythmic: dronedarone, propafenone, quinidine
 Anticancer drugs: neratinib, venetoclax
 Anti-gout: colchicine
 Antihistamines: terfenadine
 Antipsychotics/neuroleptics: lurasidone, pimozide, quetiapine
 Benign prostatic hyperplasia medicinal products: silodosin
 Cardiovascular medicinal products: eplerenone, ivabradine
 Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine
 GI motility agents: cisapride
 Immunosuppressants: voclosporin
 Lipid-modifying agents:
o HMG Co-A reductase inhibitors: lovastatin, simvastatin
o Microsomal triglyceride transfer protein (MTTP) inhibitor: lomitapide
 Migraine medicinal products: eletriptan
 Mineralocorticoid receptor antagonists: finerenone
 Neuropsychiatric agents: cariprazine
 Opioid antagonists: naloxegol
 PDE5 inhibitor: avanafil, sildenafil, tadalafil, vardenafil
 Sedative/hypnotics: clorazepate, diazepam, estazolam, flurazepam, oral midazolam and triazolam
 Vasopressin receptor antagonists: tolvaptan
Medic. prod. that are potent CYP3A inducers where significant. reduced nirmatrelvir/ritonavir plasma concentr. may be associated with the potential for loss of virologic response and possible resistance.
 Antibiotics: rifampicin, rifapentine
 Anticancer drugs: apalutamide, enzalutamide
 Anticonvulsants: carbamazepine, phenobarbital, phenytoin, primidone
 Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor
 Herbal products: St. John's wort (Hypericum perforatum)
This drug cannot be started immediately after discontinuation of CYP3A4 inducers due to the delayed offset of the recently discontinued CYP3A4 inducer.

Centrally Acting Sympathomimetics. Lisdexamfetamine 10 mg/ml.
Bottle, oral sol. 100 ml
ADHD: starting dosage in adults and ped. pts 6 years and older is 30 mg (equivalent to 3 ml) once/d in the morning. Dosage may be adj. in incr. of 10 mg (equivalent to 1 ml) or 20 mg (equivalent to 2 ml) at approx. weekly intervals up to max. dosage of 70 mg (equivalent to 7 ml) once/d.
Moderate to Severe BED in Adults: starting dosage in adults is 30 mg (equivalent to 3 ml) once /d to be titrated in incr. of 20 mg (equivalent to 2 ml) at approx. weekly intervals to achieve target dose of 50 to 70 mg (equivalent to 5 ml to 7 ml) once daily. The max. dosage is 70 mg/once daily (equivalent to 7 ml/once daily).
See prescribing info. for full details.
• Attention Deficit Hyperactivity Disorder (ADHD) in pts. ages 6 years and above.
• Mod. to Sev. Binge Eating Dis.(BED) for pts over 18 years.
C/I:Hypersens. Known hypersens. to amphetamine prod. Anaphylactic reactions, Stevens Johnson Syndrome, angioedema, and urticaria have been observed in post-marketing reports./Pts taking monoamine oxidase inhibit. (MAOIs), or within 14 days of stopping MAOIs (incl. MAOIs such as linezolid or intravenous methylene blue), because of an incr. risk of hypertensive crisis

NSAID. Flurbiprofen 8.75 mg.
Spay solution,15 ml
One dose (3 actuations= 8.75 mg Flurbiprofen ) admin. to the back of the throat every 3-6 hs as required, up to a max. of 5 doses in 24 h
Short term symptomatic relief of acute sore throat in adults
C/I: Hypersens. /Pts with hypersens. reactions (e.g asthma, bronchospasm, rhinitis, angioedema or urticaria) to acetylsalicylic acid or other NSAIDs./Active, or hist. of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulcerat.) and intestinal ulcerat./Hist. of GI bleeding or perforation, sev. colitis, haemorrhagic or haematopoietic dis. related to previous NSAID ther./Last trim. of pregn. /Sev. HF, sev. renal fail. or sev. hepatic fail./Childr. and adolesc. below 18 years.

Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg.
FC Tabs 60 X 5 mg
 Rheumatoid arthritis:
5 mg twice/d, which should not be exceeded. No dose adjust. req. when used in comb. with methotrexate (MTX).
Psoriatic arthritis: 5 mg twice/d, which should not be exceeded.
No dose adjust. req. when used in comb. with MTX.
Ankylosing spondylitis: 5 mg twice/ d.
Ulcer. colitis –Induct. tmt.: 10 mg twice/d for 8 weeks.
For pts. who do not achieve adeq. therap. benefit by week 8, induct. dose can be extend. for an addit. 8 wks. (16 wks. total), followed by 5 mg twice/d for maint. Should be discont. in pts. who show no evid. of therap. benef. by wk. 16.
Ulcer. colitis –Mainten. tmt: 5 mg twice/d.
Juvenile idiopathic arthritis (JIA) dosing as per pt. weight:
betw 10 and 20 kg: 3. 2 mg X 2 dly
betw 20-40 kg: 4 mg X 2 dly
more than 40 kg: 5 mg X 2 dly. See full prescript. details
Rheumatoid arthritis: in combin. with methotrexate (MTX) for mod. to sev. active rheumatoid arthritis (RA) in adults who have respon. inadeq. to, or who are intol. to one or more dis.-modifying antirheumatic drugs (DMARDs). Can be given as monother. in case of intoler. to MTX or when MTX is inappropriate.Psoriatic arthritis: in combin. with MTX for active psoriatic arthritis (PsA) in adults who have had an inadeq.  resp. or who have been intol. to a prior DMARD ther. Ulcerative colitis: for adults with moder. to sev. active ulcerative colitis (UC) who have had an inadeq. resp., lost resp, or were intol. to either convent. ther. or a bio. agent. Ankylosing spondylitis: for adults with active ankylosing spondylitis (AS) who have resp. inadeq. to convent. ther. Juvenile idiopathic arthritis (JIA):  for  active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in 2 years of age and older, who have resp. inadeq. to previous DMARDs. Can be given in combin. with MTX or as monother. in case of intoler. to MTX or where contin. tmt. with MTX is inapprop.
C/I: Hypersens. Active tuberc. (TB), serious infect. such as sepsis, or opportun. infect. • Severe hepatic impairm. • Pregn. and lactat.

Pazopanib 200 mg, 400 mg.
Caps 200/400 mg  X 30/60/90
800 mg once/d
Renal cell carcinoma (RCC): in adults for the first line tmt. of adv. RCC and for pts who have received prior cytokine ther. for adv. dis.
Soft tissue sarcoma (STS): for adult pts. with selective subtypes of adv. STS who have received prior chemother. for metast. dis. or who have progressed within 12 mo. after (neo) adjuvant ther.
C/I: Hypersens.

Kinase Inhibitor. momelotinib dihydrochloride 100 mg, 150 mg, 200 mg.
FC Tab  30 X 100,150,200 mg
Daily dose: 200 mg. Not to be used with other JAK inhib. CBC  and liver function to be tested before and during tmt.
Tmt. of intermediate or high-risk myelofibrosis (MF), including prim. MF or sec. MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
C/I:  Hypersens. Pregn. and lactat